A drug previously approved for adults with certain types of lymphoma or leukemia has become the first FDA approved medication for chronic graft-vs-host disease (GVHD).

Ibrutinib, marketed as Imbruvica, inhibits Bruton tyrosine kinase, a protein that plays a role in the survival and spread of malignant B cells. The medication is indicated for adults who develop chronic GVHD after a hematopoietic stem cell transplant but don’t respond to systemic therapy. An estimated 30% to 70% of patients who undergo these transplants subsequently develop chronic GVHD.

中文翻译：

---

移植物抗宿主病的救济

先前已批准用于患有某些类型的淋巴瘤或白血病的成人的药物已成为首个获得FDA批准的用于慢性移植物抗宿主病（GVHD）的药物。

依鲁替尼（Imbruvica）上市销售，可抑制Bruton酪氨酸激酶，该蛋白在恶性B细胞的存活和扩散中起着重要作用。该药物适用于造血干细胞移植后发展为慢性GVHD但对全身治疗无反应的成年人。估计接受这些移植的患者中有30％至70％随后会发展为慢性GVHD。